1. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE . (2002). Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20: 3885–3890.
2. Armitage J . (1993). Treatment of non-Hodgkin's lymphoma. N Engl J Med 328: 1023–1030.
3. Baum RP, Niesen A, Hertel A, Adams S, Koujouharoff G, Goldenberg DM et al. (2004). Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer 73 (Suppl 3): 896–899.
4. Becker WS, Behr TM, Cumme F, Rossler W, Wendler J, Kern PM et al. (1995). 67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma. Cancer Res 55: 5771s–5773s.
5. Behr TM, Holler E, Gratz S . (2002). CD22 is a suitable target molecule for detection and high-dose, myoablative radioimmunotherapy with the monoclonal antibody LL2 in acute lymphatic leukaemia and Waldenström's macroglobulinemia. Tumor Targeting 3: 32–40.